新型基因工程人肿瘤坏死因子联合VP_(16)治疗小鼠肺癌的实验研究

EXPERIMENTAL RESEARCH OF EFFECT COMBINED WITH NEW RECOMBINANT HUMAN TUMOUR NECROSIS FACTOR AND ETOPOSIDE IN MURINE PNEUMOCELLULAR CARCINOMA

目的探讨新型基因工程人肿瘤坏死因子（ｎｒｈＴＮＦ）联合足叶乙甙（ＶＰ(１６)）的协同抗肿瘤作用及ｎｒｈＴＮＦ的毒副作用、方法以复制成功的Ｌｅｗｉｓ肺癌（３ＬＬ）小鼠为模型局部用药，观察用药后移植瘤的坏死范围、抑瘤率、肺转移瘤数及ｎｒｈＴＮＦ的毒副作用。结果ｎｒｈＴＮＦ或ＶＰ(１６)瘤体内注射均能使肿瘤出现一定程度坏死，肿瘤生长及肺转移受到一定的抑制，抑瘤率分别为３３．７％、３０．４６％，肺转移瘤数与对照组比较Ｐ＜０．０５。而联合用药，肿瘤出现广泛的出血坏死，能显著抑制肿瘤生长及肺转移，抑瘤率为６５．７７％，大于理论抑瘤率５３．９１％，肺转移瘤数与对照组比较Ｐ＜０．０１。同时观察到ｎｒｈＴＮＦ对实验小鼠无明显毒副作用。结论ｎｒｈＴＮＦ和Ｖ／Ｐ(１６)联合用药，具有协同抗肿瘤作用，ｎｒｈＴＮＦ瘤体内用药，毒副反应少，安全性高。

Objective To investigate the inhibitive effects of treatment with new recombinant humantumor necrosis factor (nrhTNF) and/or etoposide (VP16) on murine lung cancer. Methods Tumor-bearingmice were randomly divided into four groups. NS, nrhTNF, VP16, nrhTNF and VP16, were respectivelyinjected into endoneoplasm in every group. Results Inhibition rate in nrhTNF group and VP16 group were33.71 % and 30. 46% respectively and resulted in tumor necrosis to a certain degree. The number of lungmetastatic tumors in the mentioned groups above were less than that in control group (P <0.05 ).Inhibition rate in nrhTNF/VP16 group was 65.77% and more extent tumor hemorrhagic necrosis thaneither in nrhTNF group or in VP16 group,and lung metastatic tumors were less than in control group (P<0. 01 ). nrhTNF had no marked side effect to mice. Conclusion nrhTNF/VP16 have synergic effect in thetreatment of Lewis lung cancer tumor.